DE69104830D1 - Darreichnungsform zur verabreichnung eines antiparkinsonsmittel. - Google Patents

Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.

Info

Publication number
DE69104830D1
DE69104830D1 DE69104830T DE69104830T DE69104830D1 DE 69104830 D1 DE69104830 D1 DE 69104830D1 DE 69104830 T DE69104830 T DE 69104830T DE 69104830 T DE69104830 T DE 69104830T DE 69104830 D1 DE69104830 D1 DE 69104830D1
Authority
DE
Germany
Prior art keywords
administrating
pharmaceutical form
antiparkinson agent
antiparkinson
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69104830T
Other languages
English (en)
Other versions
DE69104830T2 (de
Inventor
David Edgren
Howard Carpenter
Gurdish Bhatti
Atul Ayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE69104830D1 publication Critical patent/DE69104830D1/de
Application granted granted Critical
Publication of DE69104830T2 publication Critical patent/DE69104830T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
DE69104830T 1990-05-07 1991-05-01 Darreichnungsform zur verabreichnung eines antiparkinsonsmittel. Expired - Fee Related DE69104830T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/520,295 US5190763A (en) 1990-05-07 1990-05-07 Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
PCT/US1991/002995 WO1991016885A1 (en) 1990-05-07 1991-05-01 Dosage form to deliver an antiparkinson agent

Publications (2)

Publication Number Publication Date
DE69104830D1 true DE69104830D1 (de) 1994-12-01
DE69104830T2 DE69104830T2 (de) 1995-03-02

Family

ID=24071988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69104830T Expired - Fee Related DE69104830T2 (de) 1990-05-07 1991-05-01 Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.

Country Status (17)

Country Link
US (1) US5190763A (de)
EP (1) EP0527835B1 (de)
JP (1) JP2634322B2 (de)
KR (1) KR0169146B1 (de)
AT (1) ATE113203T1 (de)
AU (1) AU641770B2 (de)
CA (1) CA2041579C (de)
DE (1) DE69104830T2 (de)
DK (1) DK0527835T3 (de)
ES (1) ES2067231T3 (de)
FI (1) FI925029A (de)
IE (1) IE62397B1 (de)
NO (1) NO924209L (de)
NZ (2) NZ238011A (de)
PT (1) PT97552B (de)
WO (1) WO1991016885A1 (de)
ZA (1) ZA913282B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
EP0833671A2 (de) * 1995-06-07 1998-04-08 Noven Pharmaceuticals, Inc. Transdermale mittel, die bei raumtemperatur flüssige niedermolekulare arzneistoffe enthalten
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
DK1063981T3 (da) 1998-03-16 2002-10-14 Somerset Pharmaceuticals Inc Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
DE19855704C2 (de) 1998-12-03 2002-08-01 Lothar Saiger Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
BR0016707A (pt) 1999-12-23 2002-09-03 Pfizer Prod Inc Forma de dosagem de droga em camadas acionada por hidrogel
DZ3228A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Médicament dérivé d'un hydrogel sous forme de pastille
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
DE60231896D1 (de) * 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
EA200401334A1 (ru) * 2002-04-11 2005-04-28 Ранбакси Лабораторис Лимитед Фармацевтические композиции карбидопы и леводопы с контролируемым высвобождением
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
WO2005023185A2 (en) 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
JP2005309912A (ja) * 2004-04-23 2005-11-04 Oki Data Corp 画像形成装置
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
EP2982372B1 (de) 2005-04-05 2020-08-05 Yale University Glutamatmodulationsmittel bei der behandlung mentaler störungen
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
CA2631643C (en) * 2005-12-05 2015-07-07 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
MX2010013393A (es) * 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
JP6199539B2 (ja) * 2009-03-12 2017-09-20 デルポー，インコーポレイティド 薬物の長期送達のための埋め込み型装置
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
EP2506709B2 (de) * 2009-12-02 2019-10-09 Adamas Pharmaceuticals, Inc. Amantadinzusammensetzungen und verfahren zu ihrer verwendung
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine

Also Published As

Publication number Publication date
AU7854391A (en) 1991-11-27
DK0527835T3 (da) 1995-04-18
ES2067231T3 (es) 1995-03-16
JPH05506858A (ja) 1993-10-07
AU641770B2 (en) 1993-09-30
EP0527835A1 (de) 1993-02-24
EP0527835B1 (de) 1994-10-26
CA2041579C (en) 2003-09-30
US5190763A (en) 1993-03-02
PT97552B (pt) 1998-08-31
ZA913282B (en) 1992-02-26
FI925029A0 (fi) 1992-11-06
PT97552A (pt) 1992-01-31
FI925029A (fi) 1992-11-06
JP2634322B2 (ja) 1997-07-23
CA2041579A1 (en) 1991-11-08
NO924209L (no) 1992-11-09
WO1991016885A1 (en) 1991-11-14
IE62397B1 (en) 1995-01-25
KR0169146B1 (ko) 1999-01-15
KR930700076A (ko) 1993-03-13
NO924209D0 (no) 1992-11-02
NZ238011A (en) 1995-12-21
ATE113203T1 (de) 1994-11-15
IE911466A1 (en) 1991-11-20
NZ248491A (en) 1995-12-21
DE69104830T2 (de) 1995-03-02

Similar Documents

Publication Publication Date Title
DE69104830D1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
NO306377B1 (no) Doseform for avgivelse av et medikament
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ATE129404T1 (de) Dosierungsform fuer die freisetzung eines witkstoffs in einem kurzen zeitraum.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
YU49390A (sh) Postupak za izradu transdermalnog terapijskog sistema sa stupnjevitim otpuštanjem aktivne materije
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
NO920854L (no) Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
KR890015743A (ko) 근섬유아세포의 작용을 개선시키기 위한 tp-수용체 길항제의 용도
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
RU93043494A (ru) Способ и приспособление для воздействия ультрамалыми дозами лекарственных средств
RU94043033A (ru) Способ коррекции и модуляции иммуногомеостаза при заболеваниях внутренних органов и нервной системы
RU94042516A (ru) Способ купирования опийного абстинентного синдрома
KR910005856A (ko) 호흡기 질환 치료용 제약 조성물
RU2002129102A (ru) Лечение разделенными дозами агентов с сосудоразрушающей активностью
RU95101726A (ru) Способ повышения неспецифической резистентности организма
RU95101640A (ru) Лекарственное средство для лечения дислипопротеидемии
SE8903117D0 (sv) Laekemedel omfattande antamanid
CN1116947A (zh) 通活灵涂肤剂(搽剂)
RU93008126A (ru) Препарат воробьева

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee